Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Assessment of Guselkumab (Tremfya) and IL-17 Inhibitor Therapies in Patients With Psoriatic Arthritis in Routine Clinical Practice; A Prospective, Observational Cohort Study

NCT05049798 is registered in ClinicalTrials.gov with Janssen Pharmaceutica N.V., Belgium as lead sponsor.

NCT NCT05049798
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05049798 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Assessment of Guselkumab (Tremfya) and IL-17 Inhibitor Therapies in Patients With Psoriatic Arthritis in Routine Clinical Practice; A Prospective, Observational Cohort Study
Lead sponsor
Janssen Pharmaceutica N.V., Belgium
Phase
Observational
Overall status
Active, not recruiting
Start date
August 25, 2021
Completion date
August 2, 2027
Enrollment
1,314 (actual)
Sites
155

Conditions

As the registry lists them; a condition with its own page is linked.

arthritis, psoriatic